Cancer treatment with the antibody directed against ErbB2 rhuMAb 2C4

recombinant humanized monoclonal antibody 2C4 (rhuMAb 2C4) for use in a method for treating cancer in a patient, wherein in the method rhuMAb 2C4 is administered as a fixed dose of 420mg every three weeks, and wherein the rhuMAb 2C4 comprises the amino acid sequences of the variable heavy and light variable chains of SEQ ID nO: 3 and 4, respectively, and sequences of the constant regions of the light and heavy chains of human IgG1 (allotype not a).